Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1

Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia

(2015) J Flynn et al.   LEUKEMIA

Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era

(2014) R. Vaidya et al.   ANNALS OF ONCOLOGY

Double hit lymphoma: the MD Anderson Cancer Center clinical experience

(2014) Yasuhiro Oki et al.   BRITISH JOURNAL OF HAEMATOLOGY

Abstract 699: Optimized dosing strategies resulting in prolonged pathway inhibition enhance dinaciclib anti-tumor activity in preclinical xenograft models.

(2014) Alwin Schuller et al.   CANCER RESEARCH

Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53

(2014) G. L. Kelly et al.   GENES & DEVELOPMENT

BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma

(2014) Samantha L. Kendrick et al.   HUMAN PATHOLOGY

Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy

(2014) Elisa Oricchio et al.   JOURNAL OF EXPERIMENTAL MEDICINE

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis

(2014) Robert N. Booher et al.   PLoS One

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

(2013) C. J. Vandenberg et al.   BLOOD

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

(2013) H. Horn et al.   BLOOD

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

(2013) S. Hu et al.   BLOOD

Programming cancer cells for high expression levels of Mcl1

(2013) Franziska Ertel et al.   EMBO REPORTS

Use of Statins and the Risk of Death in Patients With Prostate Cancer

(2013) Oriana Yu et al.   JOURNAL OF CLINICAL ONCOLOGY

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

(2013) John J Nemunaitis et al.   Journal of Translational Medicine

High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?

(2013) Anupkumar George et al.   LEUKEMIA & LYMPHOMA

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency

(2012) Guo Wei et al.   CANCER CELL

Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma

(2012) Stefano Monti et al.   CANCER CELL

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Tina Marie Green et al.   JOURNAL OF CLINICAL ONCOLOGY

Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Nathalie A. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer

(2012) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma

(2012) S-S Wenzel et al.   LEUKEMIA

The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma

(2011) Elisa Oricchio et al.   CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma

(2011) Jonathan H. Schatz et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol

(2011) K A Blum et al.   LEUKEMIA

Relapsed/Refractory Diffuse Large B-Cell Lymphoma

(2011) J. W. Friedberg   Hematology-American Society of Hematology Education Program

Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era

(2010) Marita Ziepert et al.   JOURNAL OF CLINICAL ONCOLOGY

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

(2010) David Parry et al.   MOLECULAR CANCER THERAPEUTICS

Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia

(2009) Rong Chen et al.   BLOOD

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

(2009) Andrew Conroy et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity

(2008) Alessia Montagnoli et al.   Nature Chemical Biology

mTORC1 promotes survival through translational control of Mcl-1

(2008) J. R. Mills et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA